Africa In The News: Press Releases

Where Vision Meets Action: Global Africa Summit DC Unites Leaders Across Continents for Africa’s Future

Bridging continents to accelerate inclusive growth, diaspora engagement, and shared prosperity. WASHINGTON DC, DC, UNITED STATES, October 21, 2025 /⁨EINPresswire.com⁩/ -- The Global Africa Summit (GAS) – Washington DC Edition, hosted by the Africa …

SVAFF 2025 Wraps in San José: 92 Films from 32 Countries, AU ‘Sixth Region’ Announcement, Omotola Honored

92 films, 32 nations—SVAFF 2025 honored Souleymane Cissé, screened Omotola's A Mother’s Love, celebrated AU’s recognition of the diaspora as its Sixth Region. SILICON VALLEY, GA, UNITED STATES, October 21, 2025 /⁨EINPresswire.com⁩/ -- The Silicon Valley …

Avalyn Announces Multiple Presentations at the Pulmonary Fibrosis Foundation (PFF) Summit 2025

BOSTON, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on the development of inhaled therapies for the treatment of life-threatening pulmonary diseases, today announced multiple presentations at the …

Ardelyx Announces Four Abstracts Accepted for Poster Presentations at the American Society of Nephrology’s Kidney Week

WALTHAM, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today …

XORTX Announces Pricing of US$1.1 Million Registered Direct Offering

CALGARY, Alberta, Oct. 21, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and …

Discovery Announces Resource Development Agreement with Taykwa Tagamou Nation

TORONTO, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Discovery Silver Corp. (TSX: DSV, OTCQX: DSVSF) (“Discovery” or the “Company”) today announced that the Company and Taykwa Tagamou Nation (“TTN”) have entered into a Resource Development Agreement (“RDA”). The RDA …

First American Uranium Inc. Announces Addition of Former Canadian Politician Hon. Kerry-Lynne D. Findlay and Mining Veteran Joseph A. Carrabba to Board of Directors

Vancouver, BC, Oct. 21, 2025 (GLOBE NEWSWIRE) -- First American Uranium Inc. (CSE: URM) (FSE: IOR) (OTCPK: FAUMF) (“First American”, or the “Company”) is pleased to announce the appointments of the Hon. Kerry-Lynne D. Findlay and Joseph A. Carrabba to the …

Clearmind Medicine Enrolls Last Patient for the First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Vancouver, Canada, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to …

InflaRx Announces Participation in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference

JENA, Germany, Oct. 21, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced its participation in the Guggenheim Securities 2nd …

Hengrui Pharma and Kailera Therapeutics Announce Phase 3 HRS9531 Obesity Data Presentation at ObesityWeek® 2025

SHANGHAI and WALTHAM, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Hengrui Pharma (Hengrui), a global pharmaceutical company focused on scientific and technological innovation, and Kailera Therapeutics, Inc. (Kailera), a clinical-stage biopharmaceutical …

First Atlantic Nickel Announces Expanded 4-Kilometer Strike Length at RPM Zone from DTR Surface Sampling at Pipestone XL Nickel Alloy Project

GRAND FALLS-WINDSOR, Newfoundland and Labrador, Oct. 21, 2025 (GLOBE NEWSWIRE) -- First Atlantic Nickel Corp. (TSX-V: FAN) (OTCQB: FANCF) (FSE: P21) ("First Atlantic" or the "Company") is pleased to report that recent Davis Tube Recovery (DTR) surface …

MEXC Launches ENA Extravaganza with $1 Million Prize Pool, Zero-Fee Trading and Up to 600% APR Staking

VICTORIA, Seychelles, Oct. 21, 2025 (GLOBE NEWSWIRE) -- MEXC, a leading global cryptocurrency exchange, announced the launch of the ENA Extravaganza in collaboration with Ethena, offering new and existing users a $1 million prize pool alongside zero-fee …

Nxera’s Partner Cancer Research UK Presents Data from Successfully Completed Phase 1 Clinical Trial of Cancer Immunotherapy Drug HTL0039732 at ESMO

HTL0039732 (also known as NXE0039732) is Nxera’s novel oral EP4 antagonist with the potential to treat a wide range of cancers in combination with other immunotherapies HTL0039732, was found to be well-tolerated, confirmed target engagement and …

MEXC Launches SOL Launchpad: New Users Can Subscribe at 50% Off to Share 465 SOL

VICTORIA, Seychelles, Oct. 21, 2025 (GLOBE NEWSWIRE) -- MEXC, a leading global cryptocurrency exchange, has officially launched the SOL Launchpad. New users can subscribe with USDT at a 50% discount and share in a total pool of 465 SOL. Event Details Event …

Notice to holders of Icelandic Depository Receipts Simplification and streamlining of Amaroq’s securities under a single ISIN

Reykjavík, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Amaroq Ltd. (“Amaroq” or the “Company”) Notice to holders of Icelandic Depository Receipts Simplification and streamlining of Amaroq’s securities under a single ISIN TORONTO, ONTARIO – 21 October 2025 – Amaroq …

Tilkynning til handhafa íslenskra heimildarskírteina Einföldun á útgáfu hlutabréfa félagsins undir einu ISIN númeri

Reykjavík, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Amaroq Ltd. (“Amaroq” eða “félagið”) Tilkynning til handhafa íslenskra heimildarskírteina Einföldun á útgáfu hlutabréfa félagsins undir einu ISIN númeri Amaroq Ltd. (AIM, TSX-V, NASDAQ Iceland: AMRQ, OTCQX: …

PIVOT-PO Phase 3 Data Show Tebipenem HBr’s Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)

Data presented at IDWeek 2025 after study stopped early for efficacy Primary endpoint met, demonstrating non-inferiority of oral tebipenem HBr compared to intravenous treatment1 Data will be shared with regulatory authorities to support regulatory filings …

XORTX Issues Correction Notice and XORTX Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency

CALGARY, Alberta, Oct. 20, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and …